{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:00:22Z","timestamp":1791608422599,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,6]],"date-time":"2009-10-06T00:00:00Z","timestamp":1254787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> The efficacy of highly purified VWF\/FVIII concentrates with standardized ristocetin cofactor content (VWF:RCo) has been already proven in patients with von Willebrand\u2019s disease (VWD). Aim of this retrospective study is to confirm efficacy and safety of two highly purified, doubly virus\u2010inactivated VWF\/FVIII concentrates in a large cohort of patients with VWD who were characterized at enrolment by bleeding severity score. Study drugs Alphanate or Fanhdi were given to 120 cases (51 males, 69 females, median age 50\u2003years, range 6\u201383\u2003years). Patients had VWD3 (10), VWD2A (19), VWD2B (25), VWD2M (10) and DDAVP\u2010unresponsive VWD1 (56) and a median bleeding severity score of 8 (range 0\u201327). A total of 114 bleeding episodes in 55 cases and 131 surgical procedures in 85 cases could be analysed. Excellent\u2010good clinical responses were seen in 97% of bleeding episodes and in 99% of surgical procedures. To prevent recurrent gastrointestinal (GI) bleeding, cerebral (CNS) haemorrhage, haemarthroses, urogenital or multisite bleeding in more severe patients, secondary prophylaxis was also carried out in 15 cases with VWD3 (3), VWD2A (3), VWD2B (2), VWD1 (7). A median dose of 42\u2003IU VWF:RCo\u2003kg<jats:sup>\u22121<\/jats:sup> given every other day or twice a week over a median period of 334\u2003days (range 24\u2013799) prevented bleeding completely in 13 cases and reduced its incidence in the remaining two. These results confirm the efficacy and safety of the study concentrates, not only in the management of bleeding and surgery but also in secondary prophylaxis of severe VWD.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02088.x","type":"journal-article","created":{"date-parts":[[2009,10,7]],"date-time":"2009-10-07T03:12:25Z","timestamp":1254885145000},"page":"101-110","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and safety of highly purified, doubly virus\u2010inactivated VWF\/FVIII concentrates in inherited von Willebrand\u2019s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score"],"prefix":"10.1111","volume":"16","author":[{"given":"A. B.","family":"FEDERICI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"BARILLARI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"ZANON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"MAZZUCCONI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"MUSSO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"TARGHETTA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. M.","family":"MANNUCCI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,29]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890701513738"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00672.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01610.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2072"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740330902719481"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167658.85143.49"},{"key":"e_1_2_7_10_2","unstructured":"Committee for Medicinal Products For Human Use Guideline On The Clinical Investigation Of Human Plasma Derived Von Willebrand Factor Products (CPMP\/BPWG\/220\/02) November 2005 (http:\/\/www.emea.europa.eu\/pdfs\/human\/bpwg\/022002en.pdf)."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01616.x"},{"key":"e_1_2_7_13_2","unstructured":"Product Approval Information FDA Center for Biological Evaluation and Research January 21 2007 (http:\/\/www.fda.gov\/cber\/products\/alphanate.htm)."},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01570.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00688.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01784.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01847.x"},{"key":"e_1_2_7_18_2","unstructured":"FedericiAB BucciarelliP CastamanGet\u00a0al.).Incidence and determinants of bleeding in von Willebrand disease: results of the first prospective multicenter study on 814 Italian patients.http:\/\/www.haematologica.org\/cgi\/reprint\/92\/supplement_3\/1; 28 Abstract CO\u2010058."},{"key":"e_1_2_7_19_2","first-page":"125","article-title":"[Development and characterization of a high\u2010purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)]","volume":"41","author":"Ristol P","year":"1996","journal-title":"Sangre (Barc)"},{"key":"e_1_2_7_20_2","first-page":"5","article-title":"von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions","volume":"84","author":"Rivera J","year":"1999","journal-title":"Haematologica"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613747"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1160\/TH05-01-0013","article-title":"Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada \u2013 is it necessary to define a new upper reference range for factor VIII?","volume":"93","author":"Wells PS","year":"2005","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-105940"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11124"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_7_27_2","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand\u2019s factor concentrate (Haemate\u2010P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease","volume":"88","author":"Franchini M","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_7_30_2","unstructured":"BerntorpE BaghaeiF Holmstr\u00f6mMet\u00a0al.Long\u2010term prophylaxis in VWD. The Swedish experience. The International Society on Thrombosis & Haemostasis XXth Congress Sydney 2005 Australia [Abstract 01444]."},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01573.x"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_2_7_33_2","unstructured":"Summary of product characteristics of Fanhdi (Instituto Grifols S.A.) and Alphanate (Alpha Therapeutic Italia S.p.A)."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02088.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02088.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T03:53:22Z","timestamp":1698638002000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02088.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,29]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02088.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02088.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,29]]}}}